STOCKHOLM, July 4, 2024
/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT)
(NASDAQ STOCKHOLM: CALTX)
("Calliditas") today announces that its partner Viatris
Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III
clinical trial in Japan with
Nefecon, named VR-205 in the Japanese market, in Japanese patients
with IgA nephropathy (IgAN).
The clinical trial is a bridging study requiring a limited
number of Japanese patients to participate in a study similar in
design to that of the global NefIgArd trial. IgA nephropathy is a
designated retractable disease in Japan, with an estimated 33,000 patients in
Japan* assumed to be suffering
from this disease and with limited treatment options for IgAN
patients in this country.
Calliditas Therapeutics announces license agreement with Viatris
to register and commercialize specialty therapy for IgA nephropathy
in Japan - Calliditas Therapeutics
AB
*Japan Intractable Disease Information Center
CONTACT:
Åsa Hillsten, Head of IR &
Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency
of the contact persons set out above, on July 4, 2024 at 08:30 a.m.
CET.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/calliditas-therapeutics/r/launch-of-phase-3-clinical-trial-with-nefecon-in-japan,c4011121
The following files are available for download:
|
https://mb.cision.com/Main/16574/4011121/2901144.pdf
|
Viatris Trial Launch
PR_ENG
|
View original
content:https://www.prnewswire.co.uk/news-releases/launch-of-phase-3-clinical-trial-with-nefecon-in-japan-302189479.html